compare suppliers & send inquiries for free
Country of origin
Established in: 1989
6 production facilities approved by USFDA, AGES-Austria, PMDA, WHO
R&D Centers with capabilities of ANDAs, DMFs and NDDS
462+ patents filed for drug substances and polymorphs
Established in: 1941
Pilot plant & cGMP Kilolab
Human API & Veterinary API EU GMP
API and FDF production, API R&D & CDMO
Established in: 2011
MOQ: 1 g
Fast Response and Good Communication
Willingness To Start From Small
Flexible Payment Terms
Replies in a day or 2
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Eltrombopag 496775-61-2?
- Here you will find a list of producers, manufacturers and traders of Eltrombopag. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Eltrombopagum , Eltrombopag , Promacta
- Cas Number:
- DrugBank number:
- Unique Ingredient Identifier:
Here is a short description about Eltrombopag. Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
You can ask the supplier for more technical information about the product.
Eltrombopag is a type of Other antithrombin
The Other Antithrombin subcategory in pharmaceutical active pharmaceutical ingredients (APIs) refers to a class of compounds that exhibit antithrombin activity but do not fall under the traditional anticoagulant or antiplatelet categories. These APIs play a crucial role in preventing blood clot formation and reducing the risk of thrombotic events.
One notable API in this subcategory is [Name of the API], which demonstrates potent antithrombin properties by inhibiting specific clotting factors in the blood. By targeting these factors, [Name of the API] helps regulate the coagulation cascade, a complex process involved in blood clot formation.
The unique mechanism of action of [Name of the API] distinguishes it from other antithrombin APIs, making it a valuable option for treating thrombotic disorders. This API exhibits high selectivity, effectively inhibiting clotting factors without significantly impacting other blood components or processes.
[Name of the API] is carefully developed and rigorously tested to ensure its safety, efficacy, and reliability. It undergoes stringent quality control measures to meet regulatory standards and ensure consistency in its performance.
Pharmaceutical companies incorporate [Name of the API] into various formulations, such as oral tablets, injections, or topical preparations, enabling healthcare providers to administer it in the most suitable form for patients.
The Other Antithrombin subcategory in pharmaceutical APIs, with [Name of the API] as a prominent member, provides an innovative therapeutic approach to managing thrombotic disorders and contributes to enhancing patient care and outcomes in the field of hematology.
Eltrombopag (Other antithrombin), classified under Anticoagulants
Anticoagulants are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used to prevent and treat blood clotting disorders. These medications play a crucial role in various medical conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF). Anticoagulants work by inhibiting the formation of blood clots or by preventing existing clots from getting larger.
There are different types of anticoagulants available, including direct thrombin inhibitors, vitamin K antagonists, and factor Xa inhibitors. Direct thrombin inhibitors, such as dabigatran, directly target the enzyme thrombin to hinder clot formation. Vitamin K antagonists, like warfarin, interfere with the production of clotting factors that rely on vitamin K. Factor Xa inhibitors, such as rivaroxaban and apixaban, inhibit the activity of factor Xa, a crucial component in the clotting cascade.
Anticoagulants are commonly prescribed to patients at risk of developing blood clots or those with existing clotting disorders. They are often used during surgeries, such as hip or knee replacements, to minimize the risk of post-operative clot formation. Patients with AF, a condition characterized by irregular heart rhythm, may also be prescribed anticoagulants to prevent stroke caused by blood clots.
While anticoagulants offer significant benefits in preventing and treating clot-related conditions, they also carry potential risks, including bleeding complications. Patients taking anticoagulants require careful monitoring to ensure the right dosage is administered, as excessive anticoagulation can lead to hemorrhage. Regular blood tests and close medical supervision are essential to manage the delicate balance between preventing clots and avoiding excessive bleeding.
In conclusion, anticoagulants are a crucial category of pharmaceutical APIs used to prevent and treat blood clotting disorders. They function by inhibiting clot formation or preventing existing clots from enlarging. While highly beneficial, their use requires careful monitoring to minimize the risk of bleeding complications.
Eltrombopag manufacturers | traders | suppliers
We have 6 companies offering Eltrombopag from 3 different countries.
Get in contact with the supplier of your choice:
- Shilpa Medicare Ltd from India
- Saneca Pharma from Slovakia
- Shandong Octagon Chemicals Limited from China
- Raks Pharma from India
- Hetero Drugs from India
- MSN Labs. from India
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.